Cao Ka-Jia, Huang Hui-ying, Tu Ming-chi, Pan Guo-ying
Department of Radiation Oncology, Cancer Centre, Sun Yat-sen University, Guangzhou 510060, China.
Chin Med J (Engl). 2005 Aug 5;118(15):1258-62.
Brain metastasis is one of the most important causes of treatment failure in patients with small cell lung cancer (SCLC). This study was conducted to evaluate the effects of prophylactic cranial irradiation (PCI) on survival and brain metastases for patients with limited stage small cell lung cancer in complete remission.
Fifty one patients with limited stage SCLC in complete remission after chemoradiotherapy were randomly divided into PCI group (n = 26) and control group (n = 25). Patients in the PCI group received PCI at a dose of 25.2 to 30.6 Gy in 1.8 to 2.0 Gy per fraction. The Kaplan-Meier method and Log rank test were used to analyse and compare survival rates, and chi(2) test was used to compare the incidences of cranial metastases in two groups.
There was no significant difference in clinical characteristics of patients such as age, sex, effect of treatment before PCI between the two groups. The incidence of brain metastases was 3.8% in the PCI group in contrast to 32.0% in the control group (chi(2) = 5.15, P = 0.02). The 1, 3, 5-year survival rates were 84.6%, 42.3%, 34.6% respectively in the PCI group and 72.0%, 32.0%, 24.0% respectively in the control group, with no difference between the two groups (chi(2) = 2.25, P = 0.13). No serious sequelae were observed in patients receiving PCI.
For patients with limited stage SCLC responding completely to chemotherapy plus radiotherapy, PCI can decrease the incidence of brain metastases and improve survival rate.
脑转移是小细胞肺癌(SCLC)患者治疗失败的最重要原因之一。本研究旨在评估预防性颅脑照射(PCI)对局限期小细胞肺癌完全缓解患者生存及脑转移的影响。
51例放化疗后完全缓解的局限期SCLC患者随机分为PCI组(n = 26)和对照组(n = 25)。PCI组患者接受剂量为25.2至30.6 Gy、每次分割剂量为1.8至2.0 Gy的PCI。采用Kaplan-Meier法和Log rank检验分析比较生存率,采用χ²检验比较两组脑转移发生率。
两组患者年龄、性别、PCI前治疗效果等临床特征无显著差异。PCI组脑转移发生率为3.8%,而对照组为32.0%(χ² = 5.15,P = 0.02)。PCI组1、3、5年生存率分别为84.6%、42.3%、34.6%,对照组分别为72.0%、32.0%、24.0%,两组间无差异(χ² = 2.25,P = 0.13)。接受PCI的患者未观察到严重后遗症。
对于放化疗完全缓解的局限期SCLC患者,PCI可降低脑转移发生率并提高生存率。